These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The pharmacokinetics and pharmacodynamics of fosinopril in haemodialysis patients. Gehr TW; Sica DA; Grasela DM; Duchin KL Eur J Clin Pharmacol; 1993; 45(5):431-6. PubMed ID: 8112372 [TBL] [Abstract][Full Text] [Related]
7. Hemodynamic and hormonal effects of quinaprilat in patients with congestive heart failure. Mitrovic V; Mudra H; Bonzel T; Schmidt W; Strand JC; Bakovic-Alt R; Posvar EL Clin Pharmacol Ther; 1996 Jun; 59(6):686-98. PubMed ID: 8681494 [TBL] [Abstract][Full Text] [Related]
8. Fosinopril. A review of its pharmacology and clinical efficacy in the management of heart failure. Davis R; Coukell A; McTavish D Drugs; 1997 Jul; 54(1):103-16. PubMed ID: 9211084 [TBL] [Abstract][Full Text] [Related]
9. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? MacFadyen RJ; Lee AF; Morton JJ; Pringle SD; Struthers AD Heart; 1999 Jul; 82(1):57-61. PubMed ID: 10377310 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, safety, and pharmacologic effects of fosinopril sodium, an angiotensin-converting enzyme inhibitor in healthy subjects. Duchin KL; Waclawski AP; Tu JI; Manning J; Frantz M; Willard DA J Clin Pharmacol; 1991 Jan; 31(1):58-64. PubMed ID: 1646240 [TBL] [Abstract][Full Text] [Related]
11. Hemodynamic, hormonal, and pharmacokinetic aspects of treatment with lisinopril in congestive heart failure. Dickstein K J Cardiovasc Pharmacol; 1987; 9 Suppl 3():S73-81. PubMed ID: 2442558 [TBL] [Abstract][Full Text] [Related]
12. Treatment of congestive heart failure: experience with fosinopril. Blumenthal M Am J Hypertens; 1997 Oct; 10(10 Pt 2):289S-298S. PubMed ID: 9366286 [TBL] [Abstract][Full Text] [Related]
13. Acute hemodynamic and hormonal effects of lisinopril (MK-521) in congestive heart failure. Dickstein K; Aarsland T; Woie L; Abrahamsen AM; Fyhrquist F; Cummings S; Gomex HJ; Hagen E; Kristianson K Am Heart J; 1986 Jul; 112(1):121-9. PubMed ID: 3014850 [TBL] [Abstract][Full Text] [Related]
14. Fosinopril pharmacokinetics and pharmacodynamics in chronic ambulatory peritoneal dialysis patients. Gehr TW; Sica DA; Grasela DM; Fakhry I; Davis J; Duchin KL Eur J Clin Pharmacol; 1991; 41(2):165-9. PubMed ID: 1835932 [TBL] [Abstract][Full Text] [Related]
15. Single-dose and steady-state pharmacokinetics of fosinopril and fosinoprilat in patients with hepatic impairment. Ford NF; Lasseter KC; Van Harken DR; Hammett JL; Raymond R; Manning J J Clin Pharmacol; 1995 Feb; 35(2):145-50. PubMed ID: 7751424 [TBL] [Abstract][Full Text] [Related]
16. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. van de Wal RM; Plokker HW; Lok DJ; Boomsma F; van der Horst FA; van Veldhuisen DJ; van Gilst WH; Voors AA Int J Cardiol; 2006 Jan; 106(3):367-72. PubMed ID: 16337046 [TBL] [Abstract][Full Text] [Related]
17. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects. Murdoch DR; McDonagh TA; Farmer R; Morton JJ; McMurray JJ; Dargie HJ Am Heart J; 2001 May; 141(5):800-7. PubMed ID: 11320369 [TBL] [Abstract][Full Text] [Related]
18. The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril Hemodynamics Study Group. Sharma S; Deitchman D; Eni JS; Gelperin K; Ilgenfritz JP; Blumenthal M Am J Ther; 1999 Jul; 6(4):181-9. PubMed ID: 11329095 [TBL] [Abstract][Full Text] [Related]
19. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure. Cataliotti A; Boerrigter G; Chen HH; Jougasaki M; Costello LC; Tsuruda T; Lee SC; Malatino LS; Burnett JC Circulation; 2002 Feb; 105(5):639-44. PubMed ID: 11827932 [TBL] [Abstract][Full Text] [Related]
20. [Hemodynamic and humoral effects of parenteral therapy with intravenously administered ACE inhibitor quinaprilat in patients with advanced heart failure]. Mitrovic V; Mudra H; Bonzel T; Schmidt W; Schlepper M Z Kardiol; 1996 Nov; 85(11):828-38. PubMed ID: 9064945 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]